Archaeologists unveil 3,500-year-old city in Peru
The 3,500-year-old city, named Peñico, is believed to have served as a key trading hub connecting early Pacific coast communities with those living in the Andes mountains and Amazon basin.
Located some 200km north of Lima, the site lies about 600 metres (1,970 feet) above sea level and is thought to have been founded between 1,800 and 1,500 BC - around the same time that early civilisations were flourishing in the Middle East and Asia.
Researchers say the discovery sheds light on what became of the Americas' oldest civilisation, the Caral.
Drone footage released by researchers shows a circular structure on a hillside terrace at the city's centre, surrounded by the remains of stone and mud buildings.
Eight years of research at the site unearthed 18 structures, including ceremonial temples and residential complexes.
In buildings at the site, researchers discovered ceremonial objects, clay sculptures of human and animal figures and necklaces made from beads and seashells.
Peñico is situated close to where Caral, recognised as the oldest known civilisation in the Americas, was established 5,000 years ago at around 3,000 BC in the Supe valley of Peru.
Caral features 32 monuments, including large pyramid structures, sophisticated irrigation agriculture and urban settlements. It is believed to have developed in isolation to other comparative early civilisations in India, Egypt, Sumeria and China.
Dr Ruth Shady, the archaeologist who led the recent research into Peñico and the excavation of Caral in the 1990s, said that the discovery was important for understanding what became of the Caral civilisation after it was decimated by climate change.
The Peñico community was "situated in a strategic location for trade, for exchange with societies from the coast, the highlands and the jungle", Dr Shady told the Reuters news agency.
At a news conference unveiling the findings on Thursday, archaeologist Marco Machacuay, a researcher with the Ministry of Culture, said that Peñico's significance lies in it being a continuation of the Caral society.
Peru is home to many of the Americas' most significant archaeological discoveries, including the Inca citadel of Machu Picchu in the Andes and the mysterious Nazca Lines etched into the desert along the central coast.
Researchers help uncover ancient Egyptian city
Iron Age settlement and 'Roman villa' unearthed
Researchers help uncover ancient Egyptian city
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
OCD's Origins Might Not Lie in The Brain Like We Thought
Obsessive-compulsive disorder (OCD) affects up to 3 percent of people worldwide and remains one of the most challenging mental health conditions to treat effectively. That makes any fresh insight into OCD's root causes especially valuable – like a new study pointing to a surprising suspect: the bacteria living in our gut. The research from China explored how the gut microbiota – the complex community of bacteria that live in the digestive system – may influence whether a person develops OCD, and identified six types of bacteria that appear to be linked with the condition. A steady stream of studies has shown close connections between the brain and the gut, but this is the first to provide compelling evidence that gut bacteria may actually help cause it. The researchers used genetic data to strengthen the case for causation. Related: "Previous studies have indicated a potential link between the gut microbiota and OCD," write the researchers from Chongqing Medical University in their published paper. "However, the exact causal relationship remains uncertain." "Our analysis suggested that specific gut microbiota might have a causal relationship with OCD, revealing potential intervention strategies for the prevention and treatment of this disorder." To explore this link, the researchers used a genetic approach known as Mendelian randomization, which allows scientists to infer causality by analyzing genetic variants that influence both OCD and gut bacteria. They assessed links between genetic data and gut bacteria in a sample of 18,340 people, and the links between genetic data and OCD in a separate sample of 199,169 people. Although these were two discrete sets of data, the study used Mendelian randomization to essentially bridge the gap and connect gut bacteria patterns with OCD. Because our genes are fixed at birth and not shaped by environment or lifestyle, this method helps strengthen the case that gut bacteria might directly contribute to OCD, rather than just being an effect of it. However, more data and more controlled experiments will be needed to confirm a causal link. Three types of bacteria appeared to be protective against OCD: Proteobacteria, Ruminococcaceae, and Bilophila. Another three seemed to increase the risk of OCD: Bacillales, Eubacterium, and Lachnospiraceae UCG001. Interestingly, many of these bacteria have been linked with the brain before. For example, previous studies have found a connection between low levels of Ruminococcaceae species and depression. These findings expand what we already know about the gut-brain axis and how one can affect the other. "Future research should employ longitudinal designs and diverse populations to validate and expand upon these findings, as well as a more in-depth classification of microbes and their metabolic products, to further understand the role of gut microbiota in OCD," write the researchers. Down the line – and it's still a way off – we may have a new way to treat or prevent OCD, by controlling gut bacteria mixtures. For people living with the condition – and the families, friends, and clinicians who support them – this could eventually offer new hope. "Despite the utilization of cognitive behavioral therapy and selective serotonin reuptake inhibitors in OCD treatment, a notable 25–40 percent of patients experience suboptimal or no response to these interventions," write the researchers. "Moreover, the personal and societal toll of OCD is substantial." The research has been published in the Journal of Affective Disorders. The News Cycle Is a Stress Monster. But There's a Healthy Way to Stay Informed. Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer
Fast Company
2 hours ago
- Fast Company
AI could be science's strongest ally
Across the U.S. and parts of Europe, science funding is in crisis. In the U.S., a planned $18 billion worth of cuts to federal research have already halted trials, triggered mass layoffs, and shut down entire programs. Europe isn't immune either, with Horizon, Europe's flagship funding program for research and innovation, also facing rollbacks. These cuts are stretching researchers thin and slowing down innovation when we need it most. Breakthroughs in cancer, rare diseases, and drug development require time, space, and the freedom to explore. Instead, scientists are burning out and many are even walking away, with a recent Nature survey showing that 75% of U.S.-based researchers are considering relocation. With China ramping up investment in AI, the U.S. and Europe risk falling behind just as science enters its most exciting era. Agentic AI could ease the burden Scientific research is slow and expensive, not because of a lack of ideas, but because the tools haven't kept up. Knowledge is buried in siloed papers, scattered datasets, and disconnected systems, and pulling it all together takes time, money, and a lot of manual effort, slowing down even the most promising discoveries. This is where AI comes in as a true lab partner. Unlike the AI systems most of us are familiar with, agentic AI can plan and carry out tasks, all from a single prompt. Scientists can access a suite of agents that will handle the repetitive work that eats up their time, like writing reports, reviewing literature, or designing and running early-stage experiments in the lab. Tech companies and academic researchers are already starting to develop agentic AI to help achieve this. Owkin's K Navigator, Google's AI co-scientist, and Stanford's Biomni reflect a growing shift towards the adoption of agentic co-pilots that let scientists engage with their data as naturally as they would with a colleague. K Navigator is already showing that it can boost productivity by up to 20 times, giving researchers the freedom to focus on making breakthroughs. K Navigator exclusively accesses and analyses spatial multiomic data from MOSAIC Window, a subset of the largest spatial omics dataset in oncology. This allows researchers to better understand how different cells work together in the tumor micro-environment and advance vital cancer research. Agentic AI can help researchers shape hypotheses, work with complex data, and uncover insights, without needing a data science team to guide every step. This kind of acceleration will not only help researchers meet deadlines, but also open up scientific questions that might otherwise go unexplored. We hear this need from researchers every day. Many feel compelled to maintain the same high standards and deliver more data, more trials, and more publications, with fewer resources. In cancer centers and university labs alike, time is the scarcest resource. Agentic AI, embedded into real workflows, can effectively remove some of the friction that slows science down. More time on what matters AI agents won't replace critical thinking or peer review. But with the right safeguards and design (e.g. accurate source referencing and intuitive data visualization), they can help scientists spend less time on admin and more time on what really matters to advance treatments and diagnostics for patients. Because if we can't increase budgets, we need to increase impact. That means giving scientists the tools to do more with less, without burning them out or holding them back. Now is the moment to get this right, otherwise, the cost of underfunding science won't just be slower progress. It'll be lost cures, missed breakthroughs, and a generation of researchers who walk away.
Yahoo
7 hours ago
- Yahoo
Even low doses of CBD may cause harm to the liver, FDA study finds
A new clinical trial suggests there are still ongoing questions about the safety of even low doses of cannabidiol, even as CBD capsules, gummies, edibles, oils and lotions have become increasingly omnipresent in the United States in recent years. Scientists from the Food and Drug Administration's Division of Applied Regulatory Science carried out a randomized double-blind placebo-controlled trial last year to assess how low-dose CBD affects liver function in a group of healthy middle-aged men and women. Over the course of four weeks, 201 volunteers received either 5 mg per kilogram of body weight (approximately 2.3 mg per pound or the equivalent of 350 mg for a 154-pound individual) of oral CBD, or a placebo. The goal was to give them a typical amount that might be used by consumers. Participants also underwent weekly laboratory assessments. While the vast majority of people in the trial were unaffected, 5% showed greatly elevated levels of the liver enzyme aminotransferase, a known marker of liver cell damage or inflammation, according to the study published Monday in JAMA Internal Medicine. Women appeared to be more vulnerable than men. The liver enzyme returned to normal within one or two weeks of stopping CBD. Seven participants withdrew from the trial because they were showing clinical signs of potential drug-induced liver injury. The FDA didn't respond immediately to a request for comment. 'This is a significant finding, as it suggests that CBD itself, even in the absence of other drugs, may pose a risk to liver health,' says Amir Englund, a researcher at King's College London who studies cannabinoid psychopharmacology, and was not involved in the new trial. 'The results have important implications for individuals using over-the-counter CBD supplements. Many may be unaware of the potential for liver injury and assume that CBD is entirely benign.' Between 2014 and 2022, CBD product sales in the U.S. increased from $108 million to $1.9 billion, after a landmark bill passed by the Trump administration in 2018 enabled the unrestricted sale of cannabis products containing less than 0.3% THC, the psychoactive element which gets users high. According to various surveys in recent years, the majority of people in the U.S. have now heard of CBD, and around 20% have reported using CBD products in the past 12 months. While CBD products have become a popular way to self-medicate for conditions including pain, anxiety, insomnia and depression, especially among older adults, there's been little evidence on how well they work or guidance on how to use the products safely. Signs of liver injury include abdominal discomfort, jaundice or yellowing of the skin and eyes, and fatigue. However, research has shown that drug-induced liver injuries don't always become immediately apparent. In the FDA trial, only one of the participants with elevated liver enzymes noticed any symptoms within four weeks. The authors suggested that users may not realize that they are incurring harm and that doctors should ask about regular CBD use as part of routine medical screening. 'This was an important observation from the study,' said Paul Watkins, professor of pharmacy at the University of North Carolina at Chapel Hill. 'When doctors get liver chemistry results back and they're out of whack, they should be aware to ask, 'Were you taking CBD?' Because a lot of people are.' The new trial is not the first study to suggest potential health risks relating to cannabidiol and its effects on the liver. Such concerns were initially described following an FDA review of clinical trial data on CBD-based prescription drugs for childhood epilepsy, with raised liver enzymes being observed in 14% of participants. 'In clinical trials involving epilepsy patients, elevated levels of liver enzymes were among the leading causes of withdrawal from the trials due to serious adverse events,' Englund said 'However, those participants were concurrently taking other anti-epileptic medications, which could have contributed to the observed liver effects.' Watkins was subsequently involved in research investigating why CBD can affect liver cells, and he said that certain doses seem to have an effect similar to acetaminophen, or paracetamol. 'It's interesting because it's also been shown that healthy adults, when they get recurrent therapeutic doses of paracetamol, also have these liver chemistry abnormalities,' Watkins said. In the U.S., acetaminophen, when taken in excess, is among the most common causes of drug-induced liver injury, also called toxic hepatitis. In the last few years, research studies have shown that people most at risk of liver injury are those taking very high oral doses of CBD, exceeding 1000 mg per day. There have still been reports of drug-induced liver injuries in some healthy individuals taking moderate doses of anywhere between 300 mg and 1000 mg per day. Relatively little is known about why some people are more susceptible than others, but it is thought that genetic factors may play a role. According to Englund, CBD can inhibit certain enzymes in the liver which are needed for metabolizing medications. In the new FDA trial, the majority of participants who experienced the most serious liver problems also developed signs of an immune condition called eosinophilia, which is when the body produces an excess of a type of white blood cell called eosinophils. The new results emphasize the importance of tracking liver safety as a potential, unintended adverse effect, Englund said. 'Given the growing interest in CBD as a potential treatment for conditions such as psychosis and cannabis use disorder, these findings underscore the importance of monitoring liver enzyme levels in future clinical trials,' he said. Overall, Watkins — who co-chairs the Drug-Induced Liver Injury Network, a research group backed by the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health — still believes CBD is relatively safe. While over-the-counter supplements are becoming a growing potential cause of significant liver injuries, CBD has yet to be flagged as a source of concern, he said. 'Overall, the liver is very good at adjusting to sources of drug stress [indicated by elevated enzymes],' Watkins said, noting the network hasn't detected a case of serious liver injury attributed to CBD. "There could be people out there whose liver doesn't adjust very well, and as companies compete for market share, you might start getting more potent CBD which could push people into the ranges where they're getting into trouble, but the data we've got suggests it's very safe.' This article was originally published on
